8QYA | pdb_00008qya

J22.9-FNY, fully humanized, CDR optimized Fab Fragment based on chimeric J22.9-xi IgG against BCMA; with VH CDR2 glycosylation

External Resource: Annotation

Domain Annotation: SCOP2 Classification
Domain Annotation: ECOD Classification
SAbDab Antibody Annotation
Thera-SAbDab Antibody Annotation
Protein Family Annotation
Gene Ontology: Gene Product Annotation
InterPro: Protein Family Classification
Pharos: Disease Associations

Domain Annotation: SCOP2 Classification SCOP2 Database Homepage

Chains	Type	Family Name	Domain Identifier	Family Identifier	Provenance Source (Version)
C [auth A]	SCOP2B Superfamily	TNF receptor-like	8044166	3000971	SCOP2B (2022-06-29)

Domain Annotation: ECOD Classification ECOD Database Homepage

Chains	Family Name	Domain Identifier	Architecture	Possible Homology	Homology	Topology	Family	Provenance Source (Version)
C [auth A]	Myosin_head	e8qyaA01	A: a/b three-layered sandwiches	X: ATP-grasp_6	H: ATP-grasp_6	T: ATP-grasp_6	F: Myosin_head	ECOD (v294.1)
B [auth H]	Myosin_head	e8qyaH01	A: a/b three-layered sandwiches	X: ATP-grasp_6	H: ATP-grasp_6	T: ATP-grasp_6	F: Myosin_head	ECOD (v294.1)
A [auth L]	Myosin_head	e8qyaL01	A: a/b three-layered sandwiches	X: ATP-grasp_6	H: ATP-grasp_6	T: ATP-grasp_6	F: Myosin_head	ECOD (v294.1)

SAbDab Antibody Annotation SAbDab Database Homepage

Chain	Chain Class	Chain Subclass	Chain Type	Antigen Name(s)	Provenance Source
B [auth H]	Heavy Chain	IGHV4	-	chains	SAbDab (2026-03-27)
A [auth L]	Light Chain	IGKV3	Kappa	chains	SAbDab (2026-03-27)

Thera-SAbDab Antibody Annotation Thera-SAbDab Database Homepage

Chain	Name	Target	Provenance Source
B [auth H]	Pamlectabart	TNFRSF17/CD269/BCMA/TNFRSF13A, CD3E	Therapeutic SAbDab (2026-03-27)
A [auth L]	Pamlectabart	TNFRSF17/CD269/BCMA/TNFRSF13A, CD3E	Therapeutic SAbDab (2026-03-27)

Protein Family Annotation Pfam Database Homepage

Chains	Accession	Name	Description	Comments	Source
C [auth A]	PF09257	BCMA, TALL-1 binding (BCMA-Tall_bind)	BCMA, TALL-1 binding	Members of this family, which are predominantly found in the tumour necrosis factor receptor superfamily member 17, BCMA, are required for binding to tumour necrosis factor ligand TALL-1 [1].	Domain

Gene Ontology: Gene Product Annotation Gene Ontology Database Homepage

Chains	Polymer	Molecular Function	Biological Process	Cellular Component
C [auth A]	Tumor necrosis factor receptor superfamily member 17	molecular transducer activity signaling receptor activity	multicellular organismal process multicellular organismal-level homeostasis leukocyte homeostasis homeostatic process immune system process homeostasis of number of cells lymphocyte homeostasis response to stimulus immune response adaptive immune response cellular response to stimulus regulation of biological process regulation of cellular process signaling multicellular organismal process multicellular organismal-level homeostasis leukocyte homeostasis homeostatic process immune system process homeostasis of number of cells lymphocyte homeostasis response to stimulus immune response adaptive immune response cellular response to stimulus regulation of biological process regulation of cellular process signaling biological regulation cellular process signal transduction cell communication cell surface receptor signaling pathway response to cytokine cytokine-mediated signaling pathway response to peptide cellular response to tumor necrosis factor response to chemical tumor necrosis factor-mediated signaling pathway cellular response to cytokine stimulus response to tumor necrosis factor	cellular anatomical structure endomembrane system cell periphery plasma membrane membrane
B [auth H]	J22.9-FNY Fab antibody heavy chain	-	-	-
A [auth L]	J22.9-FNY Fab antibody light chain	-	-	-

InterPro: Protein Family Classification InterPro Database Homepage

Chains	Accession	Name	Type
C [auth A]	IPR022320	Tumour necrosis factor receptor 17	Family
C [auth A]	IPR015337	BCMA, TALL-1 binding	Domain
C [auth A]	IPR043521	Tumor necrosis factor receptor 13C/17	Family

Pharos: Disease Associations Pharos Homepage Annotation

Chains	Drug Target	Associated Disease
C [auth A]	Pharos: Q02223	gastric carcinoma cancer exocrine pancreatic carcinoma hepatocellular carcinoma malignant colon neoplasm osteosarcoma Relapse multiple myeloma tuberculosis cutaneous lupus erythematosus gastric cancer interstitial cystitis malignant pancreatic neoplasm periodontitis sinusitis ulcerative colitis gastric carcinoma cancer exocrine pancreatic carcinoma hepatocellular carcinoma malignant colon neoplasm osteosarcoma Relapse multiple myeloma tuberculosis cutaneous lupus erythematosus gastric cancer interstitial cystitis malignant pancreatic neoplasm periodontitis sinusitis ulcerative colitis cystic fibrosis lung cancer MALT lymphoma plasma cell myeloma Sjogren syndrome

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729. RCSB PDB uses resources of the National Energy Research Scientific Computing Center (NERSC), a Department of Energy User Facility.